“Tara wanted to help. She wanted to give back. She was someone who never lost hope.” Matt Boland givetomedicine.uchicago.edu/…

@JCO_ASCO Oncology Advances EV-202 Phase II 🧬 Enfortumab Vedotin shows activity in heavily pretreated #BreastCancer ➡️ ORR: 15.6% in HR+/HER2– | 19% in #TNBC ➡️ Median OS: 19.8 & 12.9 mo ➡️ Safety: consistent w/ urothelial data ➡️ No correlation w/ Nectin-4 expression 💬 “Results support further exploration of EV beyond urothelial carcinoma.” ascopubs.org/doi/pdf/10.1200… 👥 @antgiorda @ArifAliAwan2 @uw_hemeoncpc @UWCarbone @MSKCancerCenter @RitaNandaMD @UChicagoMed @ASCO @OncoAlert @JCO_ASCO @myESMO #ADC #OncoTwitter #TNBC #BreastCancer

Data with Enfortumab Vedotin in Patients With Previously Treated Advanced Breast Cancer (HR+/HER2- and TNBC cohorts) from the Phase II EV-202 Study are now published on JCO Oncology Advances @OncoAlert @DFCI_BreastOnc @hoperugo @RitaNandaMD ascopubs.org/doi/10.1200/OA-…

It's a good time to remind people about the role of cancer drug repositories. These nonprofits recycle donated meds to patients (after pharmacy quality checking). It saves millions. It requires legislation to support so it's a great state advocacy issue. ascopubs.org/doi/10.1200/OP-…

#ESMO25 Breaking the 6-Month PFS Ceiling after CDK4/6 Inhibition

The new BIOPSY NOW program allows patients whose #mammogram or #ultrasound are suspicious for cancer get a biospy done the same day, saving patients valuable time! Hear more from the team that made this happen: uchicagomedicine.org/forefro…

#ESMO25 - Patients with metastatic breast cancer who had received ≥ 2 years of bone modifying agents🦴were randomized to continue standard dosing (Q4W) or de-escalate to Q24W De-escalation preserved physical function without increasing skeletal events @OncoAlert

Exciting news! Join us in congratulating Hope Rugo, MD, FASCO, as the new Editor-in-Chief of the ASCO #EdBook! “In my new role, I am very excited to apply my knowledge and experience as we continue to explore expansion and maximize our reach.” Congrats @hoperugo!

Feeling anxious about that routine mammogram your doctor ordered? Watch to see how the process unfolds and how quick, easy, and painless it can be! piped.video/shorts/0DV8AP1xX… #BreastCancerAwarenessMonth #CancerScreening #Mammogram

BREAKING NEWS The Norwegian Nobel Committee has decided to award the 2025 #NobelPeacePrize to Maria Corina Machado for her tireless work promoting democratic rights for the people of Venezuela and for her struggle to achieve a just and peaceful transition from dictatorship to democracy. #NobelPrize

One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors

Day 1 of #BreastCancerAwarenessMonth: Metastatic breast cancer (MBC) is breast cancer that spreads to vital organs. It’s incurable—but research could change that. @METAvivor funds studies to stop metastasis & bring hope. #MBC #StageIVneedsMore #ResearchMatters #METober

Pembrolizumab is integral to the treatment of both early-stage and metastatic triple-negative #breastcancer. For #ASCODailyNews, @RitaNandaMD and Dr. Sarah Poland explore rechallenging with pembro after immune-related adverse events: brnw.ch/21wWdTN

Dr. Letai’s enthusiasm for scientific innovation, appreciation for the value and importance of basic research, and commitment to fostering collaboration will ensure that NCI continues to advance its mission to improve health and reduce deaths from this devastating disease.

🚨 Top Breast Cancer Data – #ESMO25 🚨 From early to metastatic settings, 13 key trials shaping practice: ✅ DESTINY-Breast11, Breast05, Breast09 ✅ monarchE, NATALEE, POSITIVE ✅ ASCENT-03, VIKTORIA-1, OptiTROP-Breast02, CULMINATE-2 & more @myESMO #esmo2025 @OncoAlert @OncBrothers

In a recent @OncLive podcast, Rita Nanda, MD (@RitaNandaMD), joins Filipa Lynce, MD (@FilipaLynce), to discuss latest clinical trial and real-world data on antibody drug conjugates used in the treatment of TNBC. @DanaFarber @uchicago_obgyn @UChicagoHemOnc ow.ly/hAwn50X2t3h

Rechallenging With Pembrolizumab After Immune-Related Adverse Events in Triple-Negative Breast Cancer: Clinical Considerations and Emerging Practice dailynews.ascopubs.org/do/re…. #ASCODailyNews @ASCO

Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer - Annals of Oncology annalsofoncology.org/article…

Here’s Stephen Colbert earning a massive standing ovation at the #Emmys and jokes "Is anyone hiring?" RETWEET if you stand with Stephen Colbert!

Thanks so much for hosting me @HMAbushukair. It was so much fun.